Kraus Al 4
4 · Cytosorbents Corp · Filed Feb 8, 2023
Insider Transaction Report
Form 4
Kraus Al
Director
Transactions
- Exercise/Conversion
Common Stock
2023-02-06$2.65/sh+12,000$31,800→ 142,046 total - Exercise/Conversion
Stock Option (right to buy)
2023-02-06−12,000→ 0 totalExercise: $2.65Exp: 2023-02-06→ Common Stock (12,000 underlying)
Footnotes (2)
- [F1]Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 72,746 shares of common stock owned by the reporting person.
- [F2]The stock options were granted to the reporting person on February 6, 2013 and were exercisable on the date of grant.